Media headlines about Cepheid (NASDAQ:CPHD) have been trending somewhat positive recently, Accern reports. The research firm ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Cepheid earned a news sentiment score of 0.19 on Accern’s scale. Accern also assigned headlines about the scientific and technical instruments company an impact score of 47.0249173737477 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
TRADEMARK VIOLATION WARNING: This news story was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another website, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2017/11/01/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-cepheid-cphd-share-price.html.
Cepheid Company Profile
Cepheid is a molecular diagnostics company. The Company develops, manufactures and markets fully-integrated systems for testing in the Clinical and Non-Clinical markets. The Company’s systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures.
Receive News & Ratings for Cepheid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cepheid and related companies with MarketBeat.com's FREE daily email newsletter.